(
MENAFN- ABN Newswire) Queanbeyan, Aug 19, 2017 AEST (ABN Newswire) - Greatcell Solar Ltd () () MD Richard Caldwell is interviewed by ABN Newswire regarding a number of significant recent developments within the company that form the precursor for the next stage of the company's growth.
The interview covered four main topics:
- Australian Renewable Energy Agency - Letter of Negotiation for a $6 Million Grant
- Recent announcement that JinkoSolar () of China were evaluating the Perovskite Solar technology for potential commercialisation in China (and globally)
- Closing of negotiations on the $2.5M CRC-P grant.
- AU$5M Capital raising via a share purchase plan to existing shareholders.
To view the video, please visit:
About Greatcell Solar Limited
Greatcell Solar Limited ()() is a global leader in the development and commercialisation of Perovskite Solar Cell (PSC) technology 3rd Generation photovoltaic technology that can be applied to glass, metal, polymers or cement. Greatcell Solar Limited manufactures and supplies high performance materials and is focussed on the successful commercialisation of PSC photovoltaics. It is a publicly listed company: Australian Securities Exchange ASX (GSL) and German Open Market (D5I). Learn more atour and subscribe to our mailing list in English and German.
About JinkoSolar Holding Co., Ltd
JinkoSolar Holding Co., Ltd. (NYSE:JKS) is a solar product manufacturer. The Company has built a vertically integrated solar product value chain from recovered silicon materials to solar modules. Its principal products are silicon wafers, solar cells and solar modules. The Company sells its products in China and to overseas markets.
MENAFN2008201701110000ID1095750950
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.